CFO transition
Kura Oncology, Inc. CFO transition: Jennifer Fulk to succeed Troy E. Wilson, Ph.D., J.D.
Kura Oncology, Inc. reported in a Form 8-K filed September 8, 2026 that Jennifer Fulk will succeed Troy E. Wilson, Ph.D., J.D. as Chief Financial Officer, principal financial officer, effective September 8, 2026.
In the filing's words
Effective as of September 8, 2026, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”) appointed Jennifer Fulk as the Company’s Chief Financial Officer, principal financial officer (replacing Troy E. Wilson, Ph.D., J.D. solely with respect to such role) and principal accounting officer (replacing Thomas Doyle solely with respect to such role).
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Kura Oncology, Inc. (KURA) |
|---|---|
| Event | Transition |
| Incoming | Jennifer Fulk |
| Outgoing | Troy E. Wilson, Ph.D., J.D. |
| Title in the filing | Chief Financial Officer, principal financial officer |
| Effective | September 8, 2026 |
| 8-K filed | September 8, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Chief Financial Officer, Soleno Therapeutics, Inc. |
| SEC CIK | 0001422143 |
Kura Oncology, Inc. reported this change in a Form 8-K, Item 5.02, filed September 8, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Jennifer Fulk? Send a correction with the primary source.